Evidence map›Paper›PMID 40399773›Full record

ArticleBMC microbiology2025

Green synthesis of silver nanoparticles using Sudanese Candida parapsilosis: a sustainable approach to combat antimicrobial resistance.

Nesreen A A Ibrahim, Humodi A Saeed, Samar M Saeed, Osama Mohamed, Omnia H Suliman, Sabah A E Ibrahim, Sofia B Mohamed

Abstract read
In one paragraph

Article in BMC microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Nesreen A A IbrahimDepartment of Microbiology, Faculty of Medical Laboratory Sciences, Sudan international university, Khartoum, Sudan.
Humodi A SaeedDepartment of Microbiology, Faculty of Medical Laboratory Sciences, Sudan University of Science and Technology, Khartoum, Sudan.
Samar M SaeedDepartment of Microbiology, College of Medical Laboratory Sciences, Sudan University of Science and Technology, Khartoum, Sudan.
Osama MohamedDepartment of Molecular Biology, National University Biomedical Research Institute, National University-Sudan, Khartoum, Sudan.
Omnia H SulimanDepartment of Medicine & Surgery, Dubai Medical University, Dubai, UAE.
Sabah A E IbrahimBioinformatics and Biostatistics Department, National University Biomedical Research Institute, National University, Khartoum, Sudan.
Sofia B MohamedBioinformatics and Biostatistics Department, National University Biomedical Research Institute, National University, Khartoum, Sudan. sofiabashir2002@gmail.com.

Funding

National University Biomedical Research Institute, National University-Sudan NUSU-2023455
6 · The paper itself

Abstract

backgroundAntimicrobial resistance (AMR) is a critical global health challenge, particularly in Sudan, where the overuse and misuse of antibiotics have driven the rise of multidrug-resistant (MDR) pathogens. Conventional antimicrobial strategies often fall short due to rapid resistance development and limited efficacy, highlighting the need for novel approaches. Nanotechnology offers promising alternatives, with silver nanoparticles (AgNPs) demonstrating potent broad-spectrum antimicrobial activity. This study aims to develop an eco-friendly synthesis of AgNPs using Candida parapsilosis (C. parapsilosis), an untapped yeast strain isolated from Sudanese soil, to combat AMR.

resultsBiosynthesis of AgNPs using C. parapsilosis was successfully confirmed through UV-Vis spectroscopy, X-ray diffraction (XRD), and high-resolution transmission electron microscopy (HRTEM), revealing well-defined nanoparticles. The biosynthesized AgNPs exhibited strong antibacterial activity against both ATCC reference strains and MDR clinical isolates of Gram-positive and Gram-negative bacteria, with inhibition zones increasing in a concentration-dependent manner. At optimal concentrations, inhibition zones reached 29 mm for Pseudomonas aeruginosa (P.aeruginosa) (ATCC 27853), while clinical isolates of Salmonella typhi (S. typhi) (24.5 ± 0.58 mm) and Escherichia coli (E. coli) (23.8 ± 0.79 mm) exhibited significant susceptibility. Minimum inhibitory concentration (MIC) and minimum bactericidal concentration (MBC) assays demonstrated potent bactericidal activity, particularly against E. coli and Klebsiella pneumoniae (K. pneumoniae) at 0.3125 mg/mL. Furthermore, AgNPs synergistically enhanced the efficacy of conventional antibiotics in a species- and antibiotic-dependent manner. The strongest synergy was observed in Enterococcus faecalis (E. faecalis) (up to 9.84-fold with Colistin) and Acinetobacter baumannii (A. baumannii) (up to 5.11-fold with Ceftazidime), suggesting that AgNP-enhanced antibiotic efficacy varies depending on bacterial species, nanoparticle synthesis method, and antibiotic type.

conclusionsThis study presents a novel and sustainable approach to tackling AMR by leveraging Sudanese yeast strains for the green synthesis of AgNPs. The findings underscore the potential of AgNPs as an effective antibacterial agent, both independently and in combination with conventional antibiotics, to combat MDR pathogens. By integrating microbiology and nanotechnology, this research offers a cost-effective and environmentally friendly solution for AMR mitigation. These findings provide a strong foundation for future clinical applications and public health interventions, particularly in resource-limited settings.

Indexed as

Anti-Bacterial AgentsCandida parapsilosisGreen Chemistry TechnologyMetal NanoparticlesSilverDrug Resistance, Multiple, BacterialGram-Negative BacteriaMicrobial Sensitivity TestsSudanAnti-Bacterial AgentsSilverAntibacterial activity, membrane integrityCandida parapsilosisGreen synthesisSilver nanoparticles

Identifiers

PMID40399773
PMCPMC12093675

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.